

SUPPLEMENTARY TABLE S2. DEMOGRAPHIC DATA AND CLINICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS TESTED FOR SERUM LEVELS OF BONE MORPHOGENETIC PROTEIN-2

<i>Patient no.</i>	<i>Sex Age (years)</i>	<i>Disease Duration (months)</i>	<i>SLEDAI</i>	<i>Clinical manifestations</i>	<i>Therapy</i>
1	F/41	40	11	Cytopenia, hemophagocytic lymphohistiocytosis	Pred, HCQ
2	F/18	48	4	Nephritis, cytopenia	Pred, LEF, HCQ
3	F/34	84	10	Nephritis, cytopenia	Pred, CYC, HCQ
4	F/52	122	15	Nephritis, cytopenia, interstitial pneumonia	Pred, CYC, MMF
5	F/54	120	10	Nephritis, seizures	Prod, CYC, HCQ
6	F/27	180	2	Cytopenia	Pred, CYC, HCQ
7	F/45	10	11	Nephritis, cytopenia	Pred, HCQ
8	M/13	15	9	Nephritis	Pred, HCQ
9	F/57	108	9	Nephritis, interstitial pneumonia	Pred, HCQ, CsA
10	F/46	17	9	Nephritis, cytopenia, arthralgia	Pred, HCQ
11	F/18	15	18	Nephritis, arthralgia,	Pred, CYC, HCQ
12	F/17	6	8	Cytopenia, arthralgia	Pred, HCQ
13	F/25	5	9	Nephritis	Pred, CYC, HCQ
14	F/27	36	2	Femur head necrosis	Pred, HCQ, HCQ
15	F/18	36	15	Vasculitis	Pred, HCQ
16	F/41	1	21	Nephritis, cytopenia, vasculitis	Pred, CYC, HCQ

Pred, prednisone; CYC, cyclophosphamide; HCQ, hydroxychloroquine; LEF, leflunomide; CsA, cyclospori.